The U.S. Food and Drug Administration has approved the final product label for Syndros, a cannabis-based oral solution used to treat weight loss in cancer and AIDS patients.

Drug maker, Insys Therapeutics, said the approval marks a milestone for the company, as the last regulatory step before product launch.

Syndros is the second product developed and commercialized by the Phoenix-based drug maker.

Its primary product, Subsys, an opioid-based nasal spray, has been the subject of a federal investigation into whether Insys bribed doctors to prescribe the drug.

The most recent case ended in the doctor being sentenced to 21 years in prison.